Qiagen (QGEN) Cash & Equivalents (2009 - 2026)

Qiagen has reported Cash & Equivalents for 18 years, with the latest figure at $646.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 1.18% year-over-year to $646.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $646.3 million (up 1.18% YoY) and the FY2025 annual result came in at $839.0 million, up 26.44% from the prior year.
• Cash & Equivalents slipped to $646.3 million in Q1 2026 per QGEN's latest filing, from $839.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.4 billion in Q3 2025 and troughed at $359.2 million in Q1 2023.
• A 5-year average of $741.4 million and a median of $665.8 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 105.91% in 2022, then tumbled 54.39% in 2023.
• Over 5 years, Cash & Equivalents stood at $1.3 billion in 2022, then tumbled by 47.46% to $668.1 million in 2023, then slipped by 0.68% to $663.6 million in 2024, then advanced by 26.44% to $839.0 million in 2025, then decreased by 22.97% to $646.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $646.3 million, $839.0 million, and $1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.